The open access joint statement was published in the International Journal of Gynecological Cancer February 12, 2020.
European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis
Authors: Margaret Rees, Roberto Angioli, Robert Coleman, Rosalind M Glasspool, Francesco Plotti, Tommaso Simoncini and Corrado Terranova
Worldwide, it is estimated that about 1.3 million new gynecological cancer cases are diagnosed each year.
Management of menopausal symptoms and the prevention and treatment of osteoporosis in women with gynecological cancer needs to be individualized, with or without menopausal hormone therapy, according to tumor type and stage, and the woman’s age.
In women who are taking anti-estrogenic therapies such as aromatase inhibitors, estrogen-based therapies are contraindicated and non-hormonal options are recommended as initial therapy.